# Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

> **NCT01818063** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 9 (actual)

## Conditions studied

- Estrogen Receptor-negative Breast Cancer
- HER2-negative Breast Cancer
- Progesterone Receptor-negative Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Triple-negative Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT01818063
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-25
- **Primary completion:** 2015-03-01
- **Final completion:** 2018-12-10
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01818063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01818063, "Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01818063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*